Stock Price & Analysis

Based on the recent market data and technical analysis, here is a concise assessment of TMO stock:

Technical Analysis

• Stock is showing a short-term uptrend with recent price at $538.98, up 0.64% in post-market trading
• Currently trading between key Fibonacci levels - support at $523.24 and resistance at $556.37
• RSI-14 at 41.85 indicates neutral momentum but approaching oversold territory
• MACD showing bearish divergence with -7.45 reading

Recent Developments

• Company just filed for automatic mixed securities shelf registration, indicating potential future capital raising plans
• Facing significant headwinds ahead of Q4 2024 earnings

Analyst Sentiment

• Mixed analyst ratings with recent actions:
  • Raymond James: Buy rating with $605 PT (1.23% upside)
  • RBC Capital: Buy rating with $642 PT (7.42% upside)
  • Barclays: Downgraded to Hold with $555 PT
  • Bernstein: Downgraded to Hold

Recommendation: HOLD at current levels. While TMO shows some positive technical signals and analyst support, the mixed ratings and potential dilution from the new shelf registration suggest caution. Wait for more clarity on Q4 earnings and capital raising plans before establishing new positions.

Based on the provided data and recent analyst reports, here's a price prediction analysis for TMO stock in 2025:

Technical Analysis

Current Market Position:

• Current price: $538.98 (as of Feb 24, 2025)
• Trading below both 200-day SMA ($568.89) and 250-day SMA ($569.89)
• RSI-14 at 41.85 indicates neutral momentum but approaching oversold territory
• MACD showing bearish momentum with -7.45 and negative histogram

Fundamental Drivers:

• Strong Q4 2024 performance with revenue of $11.395B (+5% YoY) and adjusted EPS of $6.10, beating estimates
• Management provided 2025 guidance:
  • Revenue: $43.5B-$44B (3-4% organic growth)
  • Adjusted EPS: $23.10-$23.50 (6-8% YoY growth)

Analyst Outlook:

• Jefferies maintains Buy rating with strong confidence in margin expansion and EPS growth
• Bank of America Securities maintains Buy rating with $660 price target
• Multiple analysts have raised price targets:
  • Morgan Stanley: Named TMO a "Top Pick"
  • Bernstein: $690 (from $630)
  • RBC Capital: $693
  • Baird: $660
  • Wells Fargo: $680

2025 Price Prediction: Based on technical analysis, fundamental outlook and analyst consensus:

• Base case: $625-645 (16-20% upside)
  • Driven by continued margin expansion and EPS growth
• Bull case: $680-700 (26-30% upside)
  • If exceeding organic growth guidance and further margin improvements
• Bear case: $520-540 (current levels)
  • If macro headwinds persist or growth falls below guidance

Most likely scenario: Base case ($625-645) with 60% probability, supported by:

1. Strong operational execution and margin expansion
2. Conservative 2025 guidance leaving room for upside
3. Broad analyst confidence in growth trajectory

The S1 support level for TMO Stock is $522.23 ,The R1 resistant level for TMO Stock is $541.11.

As of the end of day on 2025-02-27, the price of TMO Stock was $525.96.

The target price for TMO Stock according to analyst rating is 665.22, with the highest price target at 715.00 and the lowest at 585.00. Analysts have a Strong Buy rating on TMO Stock overall.

The market cap of TMO is $197.4B.

Based on the provided data and recent analyst reports, here's a comprehensive analysis of TMO's valuation:

Technical Analysis

The stock is currently showing bearish momentum with RSI at 40.00 and MACD divergence (-7.32, -5.36), indicating downward pressure. The stock is trading below both its 200-day SMA ($569.08) and 250-day SMA ($570.00), suggesting a bearish trend.

Fundamental Valuation

The stock appears overvalued based on several metrics:

1. Declining Growth: Revenue decreased from $44.9B (2022) to $42.8B (2023), representing a -4.6% YoY decline.

2. Margin Compression:

• Gross margin declined from 42.24% to 39.90%
• Net margin decreased from 15.50% to 13.90%
• ROE dropped from 16.40% to 13.22%

3. Multiple Expansion: Despite weaker fundamentals, valuation multiples have increased:

• P/E ratio increased from 31.22 (Q4 2022) to 34.35 (Q4 2023)
• EV/EBITDA expanded from 20.22 to 21.57

Recent Analyst Views According to recent analyst reports:

• Jefferies maintains Buy rating with positive outlook on margin expansion
• Bank of America Securities maintains Buy rating with $660 price target
• However, these ratings were given before the recent market decline

Conclusion: TMO appears overvalued at current levels due to:

• Deteriorating fundamental metrics
• Trading at premium multiples despite growth challenges
• Technical indicators showing bearish momentum
• Current price ($532.55) still represents high multiples relative to declining growth

Thermo Fisher Scientific Inc. is engaged in helping life sciences research, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. The Company's Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Analytical Instruments segment provides instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. The Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory.

Based on the available data and recent market analysis, here is a comprehensive price prediction for TMO stock in 2030:

TMO stock is projected to reach $750-800 by 2030, driven by three key factors:

1. Strong Growth Fundamentals: Recent analyst reports indicate robust growth potential, with Jefferies maintaining a Buy rating and highlighting significant operating margin expansion. The company's 2025 guidance shows 3-4% organic growth with EPS of $23.10-$23.50, suggesting a steady growth trajectory.

2. Market Leadership & Innovation: TMO maintains dominant positions across Life Sciences, Analytical Instruments, and Laboratory Products segments, with Q4 2024 showing growth across all segments. This diversified revenue stream provides stability for long-term growth.

3. Strategic Positioning: Bank of America Securities maintains a Buy rating, citing TMO's strong competitive positioning and diverse portfolio, particularly in high-end analytical instrumentation.

TMO has a total of 122000 employees.